Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.

There was also a 65% relative reduction in COVID-related medical visits (95% CI 24.4-83.8) with nirmatrelvir-ritonavir versus ...

Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary ...

Cover, a Missouri-based Insurtech that provides algorithmic underwriting, QUItm based eApp Service and Policy Administration for life insurance companies launches iCover Directtm ( a Life, Health and ...

Insights speaks directly to the people with an inside track on the big issues. Here, Dan Glass demands drug company Gilead ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

Kite Pharma, the California-based cell therapy subsidiary of Gilead Sciences, plans to shut down its Philadelphia office. "We ...

The Washington State Employment Security Department said in the filing that 72 employees will be laid off on Jan. 17. A ...

At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias ...